Previous 10 | Next 10 |
Thinly traded nano cap Salarius Pharmaceuticals (NASDAQ: SLRX ) craters 53% premarket on robust volume in reaction to its public offering of ~7.1M Class A Units at $1.15 and ~1.2M Class B Units at $1.15. More news on: Salarius Pharmaceuticals, Inc., Healthcare stocks news, St...
HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $9.6 million, prior to de...
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the BIO CEO & Inves...
Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study Data Supports Continued Study of Seclidemstat with Checkpoint Inhibitors HOUSTON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Salarius Phar...
Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP ) +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...
Salarius Pharmaceuticals (NASDAQ: SLRX ) has filed a preliminary prospectus for a $6.9M public offering of Class A & B units. More news on: Salarius Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics, announced today that its chief executive officer, David Arthur, will presen...
HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion leader (KOL) call on Epigenetics, Thursday, December 19 th at 12pm Ea...
Axsome Therapeutics (NASDAQ: AXSM ) +82% on positive AXS-05 data in MDD. More news on: Axsome Therapeutics, Inc., Camber Energy, Inc., Salarius Pharmaceuticals, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Salarius Pharmaceuticals (NASDAQ: SLRX ) is up 12% premarket on increased volume in reaction to Fast Track designation in the U.S. for lead candidate seclidemstat for the treatment of a rare pediatric bone cancer called Ewing sarcoma. More news on: Sala...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NASDAQ Market:
Salarius Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is one of today's top gainers. The company's shares have moved 57.21% on the day to $3.37. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Secli...
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...